ArticleCancers2022
In Situ
Article in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 24 citations in OpenAlex.
- A photocleavable peptidic Ru(ii) mass-tag enabling targeted DESI and MALDI mass spectrometry imaging in cancer tissues.Chemical science · 2026Article
- High-MannoseJournal of proteome research · 2026Article
- Glycomics in Human Diseases and Its Emerging Role in Biomarker Discovery.Biomedicines · 2025Review
- Deciphering distinct spatial alterations in N-glycan expression profiles in the spinal cord and brain of male rats in a neuropathic pain model.Cellular & molecular biology letters · 2025Article
- Glycan diversity in ovarian cancer: Unraveling the immune interplay and therapeutic prospects.Seminars in immunopathology · 2024Review
- Recent Developments and Application of Mass Spectrometry Imaging in N-Glycosylation Studies: An Overview.Mass spectrometry (Tokyo, Japan) · 2024Review
- 6-PlexAnalytical chemistry · 2023Article
- Enhanced Detection of ChargedAnalytical chemistry · 2023Article
- Review
- In Situ Imaging of O-Linked β-N-Acetylglucosamine Using On-Tissue Hydrolysis and MALDI Mass Spectrometry.Cancers · 2023Article
- Capitalizing glycomic changes for improved biomarker-based cancer diagnostics.Exploration of targeted anti-tumor therapy · 2023Review
- Device-Controlled Microcondensation for Spatially Confined On-Tissue Digests in MALDI Imaging ofPharmaceuticals (Basel, Switzerland) · 2022Article
- Spatial Mapping of PlantFrontiers in plant science · 2022Article
- Advances in mass spectrometry imaging for spatial cancer metabolomics.Mass spectrometry reviewsReview
- Mass spectrometry imaging of N-linked glycans: Fundamentals and recent advances.Mass spectrometry reviewsReview
- Analysis of carbohydrates and glycoconjugates by matrix-assisted laser desorption/ionization mass spectrometry: An update for 2021-2022.Mass spectrometry reviewsReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
The particularly high mortality of epithelial ovarian cancer (EOC) is in part linked to limited understanding of its molecular signatures. Although there are data available on in situ
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.